[go: up one dir, main page]

AR087995A1 - Derivados de n-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}fenil)-n-(4-fluorofenil)ciclopropan-1,1-dicarboxamida - Google Patents

Derivados de n-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}fenil)-n-(4-fluorofenil)ciclopropan-1,1-dicarboxamida

Info

Publication number
AR087995A1
AR087995A1 ARP120103501A ARP120103501A AR087995A1 AR 087995 A1 AR087995 A1 AR 087995A1 AR P120103501 A ARP120103501 A AR P120103501A AR P120103501 A ARP120103501 A AR P120103501A AR 087995 A1 AR087995 A1 AR 087995A1
Authority
AR
Argentina
Prior art keywords
metiloxi
dicarboxamida
ciclopropan
oxi
quinolin
Prior art date
Application number
ARP120103501A
Other languages
English (en)
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of AR087995A1 publication Critical patent/AR087995A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/108—Osteoporosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Quinoline Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Reivindicación 1: Un método para tratar osteoporosis, que comprende la administración a un paciente que necesita de dicho tratamiento de un compuesto de la fórmula (1), o sus sales farmacéuticamente aceptables, en donde: R¹ es halo; R² es halo; R³ es alquilo C₁₋₆; R⁴ es alquilo C₁₋₆; y Q es CH o N. Reivindicación 3: El método de acuerdo con las reivindicaciones 1 - 2, en donde el compuesto de la fórmula (1) es el compuesto de fórmula (2), o sus sales farmacéuticamente aceptables.
ARP120103501A 2011-09-22 2012-09-21 Derivados de n-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}fenil)-n-(4-fluorofenil)ciclopropan-1,1-dicarboxamida AR087995A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161538039P 2011-09-22 2011-09-22

Publications (1)

Publication Number Publication Date
AR087995A1 true AR087995A1 (es) 2014-04-30

Family

ID=47010756

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120103501A AR087995A1 (es) 2011-09-22 2012-09-21 Derivados de n-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}fenil)-n-(4-fluorofenil)ciclopropan-1,1-dicarboxamida

Country Status (18)

Country Link
US (1) US10166225B2 (es)
EP (2) EP3275443A1 (es)
JP (1) JP6240075B2 (es)
KR (1) KR20140069133A (es)
CN (1) CN103957915A (es)
AR (1) AR087995A1 (es)
AU (1) AU2012312364B2 (es)
BR (1) BR112014006702A2 (es)
CA (1) CA2848512A1 (es)
EA (1) EA201490676A1 (es)
ES (1) ES2639093T3 (es)
GE (1) GEP201606523B (es)
IL (1) IL231495B (es)
MX (1) MX351133B (es)
TW (1) TWI564009B (es)
UA (1) UA115866C2 (es)
WO (1) WO2013043840A1 (es)
ZA (1) ZA201401728B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250123237A (ko) 2009-01-16 2025-08-14 엑셀리시스, 인코포레이티드 암의 치료를 위한 ｎ-（４-｛〔６，７-비스（메틸옥시）퀴놀린-4-일〕옥시｝페닐）-ｎ＇-（４-플루오로페닐）사이클로프로판-1,1-디카르복사미드의 말산염 및 그 결정형
SI2621481T2 (sl) 2010-09-27 2023-02-28 Exelixis, Inc., Dvojni inhibitorji MET in VEGF za zdravljenje proti kastraciji odpornega raka prostate in osteoblastnih kostnih metastaz
AU2012214322B2 (en) 2011-02-10 2017-04-27 Exelixis, Inc. Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds
US20120252840A1 (en) 2011-04-04 2012-10-04 Exelixis, Inc. Method of Treating Cancer
JP2014513129A (ja) 2011-05-02 2014-05-29 エクセリクシス， インク． 癌および骨癌疼痛の治療方法
US10166225B2 (en) 2011-09-22 2019-01-01 Exelixis, Inc. Method for treating osteoporosis
US9365516B2 (en) 2011-10-20 2016-06-14 Exelixis, Inc. Process for preparing quinoline derivatives
HK1207587A1 (en) 2012-05-02 2016-02-05 Exelixis, Inc. A dual met - vegf modulator for treating osteolytic bone metastases
AU2014232714B2 (en) 2013-03-15 2018-07-19 Exelixis, Inc. Metabolites of N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide
ES2927651T3 (es) 2013-04-04 2022-11-10 Exelixis Inc Forma de dosificación de cabozantinib y uso en el tratamiento del cáncer
US10501418B2 (en) 2014-02-14 2019-12-10 Exelixis, Inc. Crystalline solid forms of N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N′-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use
MA39735A (fr) 2014-03-17 2017-01-25 Exelixis Inc Dosage de préparations de cabozantinib
CN104788372B (zh) * 2014-07-25 2018-01-30 上海圣考医药科技有限公司 一种氘代卡博替尼衍生物、其制备方法、应用及其中间体
EP3174854B1 (en) * 2014-07-31 2022-08-24 Exelixis, Inc. Method of preparing fluorine-18 labeled cabozantinib and its analogs
AU2015301097B2 (en) 2014-08-05 2021-03-04 Exelixis, Inc. Drug combinations to treat multiple myeloma
CA3020749A1 (en) 2016-04-15 2017-10-19 Exelixis, Inc. Method of treating renal cell carcinoma using n-(4-(6,7-dimethoxyquinolin-4-yloxy) phenyl)-n'-(4-fluoropheny)cyclopropane-1,1-dicarboxamide, (2s)-hydroxybutanedioate
JP7166292B2 (ja) 2017-05-26 2022-11-07 エグゼリクシス， インコーポレイテッド Ｎ－｛４－［（６，７－ジメトキシキノリン－４－イル）オキシ］フェニル｝－ｎ’－（４－フルオロフェニル）シクロプロパン－１，１－ジカルボキサミドの塩の結晶性固体形態、製造プロセス、及び使用方法
CN110678180A (zh) * 2017-06-09 2020-01-10 埃克塞里艾克西斯公司 治疗癌症的液体剂型
EP4647127A3 (en) 2018-01-26 2025-12-17 Exelixis, Inc. Compounds for the treatment of kinase-dependent disorders
WO2019241504A1 (en) 2018-06-15 2019-12-19 Handa Pharmaceuticals, Llc Kinase inhibitor salts and compositions thereof
US12303615B2 (en) * 2020-11-19 2025-05-20 University Of Massachusetts Demineralized bone paper
EP4658271A1 (en) 2023-01-31 2025-12-10 Handa Oncology, LLC Improved cabozantinib compositions and methods of use

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
CA2452390A1 (en) * 2001-06-29 2003-01-09 Ab Science Use of tyrosine kinase inhibitors for treating bone loss
ES2925655T3 (es) * 2003-09-26 2022-10-19 Exelixis Inc Moduladores c-Met y métodos de uso
AU2005270068B2 (en) 2004-07-02 2012-04-19 Exelixis, Inc. C-Met modulators and method of use
JP4572269B2 (ja) * 2004-11-25 2010-11-04 財団法人ヒューマンサイエンス振興財団 癌の骨転移のリスクの予測方法
WO2006108059A1 (en) 2005-04-06 2006-10-12 Exelixis, Inc. C-met modulators and methods of use
CA2658725A1 (en) 2006-08-16 2008-02-21 Exelixis, Inc. Using pi3k and mek modulators in treatments of cancer
WO2008044379A1 (fr) * 2006-10-11 2008-04-17 Oriental Yeast Co., Ltd. Modèle animal de perte osseuse
TR201900306T4 (tr) 2006-12-14 2019-02-21 Exelixis Inc Mek inhibitörlerini kullanma yöntemleri.
US20080200515A1 (en) 2006-12-29 2008-08-21 Tap Pharmaceutical Products Inc. Solid state forms of enantiopure ilaprazole
EP2131810B1 (en) * 2007-03-02 2011-05-04 Novartis AG Oral administration of a calcitonin
CA2685962A1 (en) * 2007-05-08 2009-02-05 Burnham Institute For Medical Research Tissue non-specific alkaline phosphatase inhibitors and uses thereof for treating vascular calcification
CL2008002775A1 (es) * 2007-09-17 2008-11-07 Amgen Inc Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
WO2009079471A1 (en) * 2007-12-14 2009-06-25 Amgen Inc. Method for treating bone fracture with anti-sclerostin antibodies
JP5010034B2 (ja) * 2007-12-28 2012-08-29 エフ．ホフマン−ラ ロシュ アーゲー 生理学的状態の評価
UY31800A (es) 2008-05-05 2009-11-10 Smithkline Beckman Corp Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb
AR075084A1 (es) 2008-09-26 2011-03-09 Smithkline Beecham Corp Metodo de preparacion de quinolinil -oxidifenil - ciclopropanodicarboxamidas e intermediarios correspondientes
EP2349328A1 (en) 2008-10-01 2011-08-03 Ludwig Institute For Cancer Research Methods for the treatment of cancer
TW201022258A (en) 2008-11-13 2010-06-16 Exelixis Inc Methods of preparing quinoline derivatives
WO2010065838A1 (en) 2008-12-04 2010-06-10 Exelixis, Inc. Methods of preparing quinoline derivatives
KR20250123237A (ko) 2009-01-16 2025-08-14 엑셀리시스, 인코포레이티드 암의 치료를 위한 ｎ-（４-｛〔６，７-비스（메틸옥시）퀴놀린-4-일〕옥시｝페닐）-ｎ＇-（４-플루오로페닐）사이클로프로판-1,1-디카르복사미드의 말산염 및 그 결정형
MX2012000809A (es) 2009-07-17 2012-03-14 Exelixis Inc Formas cristalinas de n-[3-fluoro-4-({6-(metiloxi)-7-[(3-morfolin- 4-ilpropil)oxi]-quinolin-4-il}oxi)fenil]-n'-(4-fluorofenil)ciclop ropan-1,1-dicarboxamida.
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
TW201202228A (en) 2010-03-12 2012-01-16 Exelixis Inc Hydrated crystalline forms of N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]-quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1, 1-dicarboxamide
US20120070368A1 (en) 2010-04-16 2012-03-22 Exelixis, Inc. Methods of Using C-Met Modulators
WO2012009723A1 (en) 2010-07-16 2012-01-19 Exelixis, Inc. C-met modulator pharmaceutical compositions
AU2011278950C1 (en) 2010-07-16 2018-11-22 Exelixis, Inc. c-Met modulator pharmaceutical compositions
RU2013114360A (ru) * 2010-08-31 2014-10-10 Дженентек, Инк. Биомаркеры и способы лечения
CA2812753A1 (en) 2010-09-27 2012-04-05 Exelixis, Inc. Dual inhibitors of met and vegf for the treatment of castration resistant prostate cancer and osteoblastic bone metastases
SI2621481T2 (sl) 2010-09-27 2023-02-28 Exelixis, Inc., Dvojni inhibitorji MET in VEGF za zdravljenje proti kastraciji odpornega raka prostate in osteoblastnih kostnih metastaz
EP2621483A1 (en) 2010-09-27 2013-08-07 Exelixis, Inc. Dual inhibitors of met and vegf for the treatment of castration resistant prostate cancer and osteoblastic bone metastases
WO2012071321A1 (en) 2010-11-22 2012-05-31 Glaxosmithkline Llc Method of treating cancer
AU2012214322B2 (en) 2011-02-10 2017-04-27 Exelixis, Inc. Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds
US20120252840A1 (en) 2011-04-04 2012-10-04 Exelixis, Inc. Method of Treating Cancer
JP2014513129A (ja) 2011-05-02 2014-05-29 エクセリクシス， インク． 癌および骨癌疼痛の治療方法
TW201306842A (zh) 2011-06-15 2013-02-16 Exelixis Inc 使用ｐｉ３ｋ／ｍｔｏｒ吡啶並嘧啶酮抑制劑及苯達莫司汀及／或利妥昔單抗治療惡性血液疾病之組合療法
US10166225B2 (en) 2011-09-22 2019-01-01 Exelixis, Inc. Method for treating osteoporosis
US9365516B2 (en) 2011-10-20 2016-06-14 Exelixis, Inc. Process for preparing quinoline derivatives
TW201323864A (zh) 2011-11-08 2013-06-16 Exelixis Inc 定量癌症治療之方法
WO2013070890A1 (en) 2011-11-08 2013-05-16 Exelixis, Inc. Dual inhibitor of met and vegf for treating cancer
HK1207587A1 (en) 2012-05-02 2016-02-05 Exelixis, Inc. A dual met - vegf modulator for treating osteolytic bone metastases
CN114129566A (zh) 2012-09-07 2022-03-04 埃克塞里艾克西斯公司 用于治疗肺腺癌的met、vegfr和ret的抑制剂

Also Published As

Publication number Publication date
EP2758057A1 (en) 2014-07-30
CN103957915A (zh) 2014-07-30
IL231495B (en) 2019-03-31
JP6240075B2 (ja) 2017-11-29
TW201313232A (zh) 2013-04-01
JP2014527984A (ja) 2014-10-23
WO2013043840A1 (en) 2013-03-28
US20140228401A1 (en) 2014-08-14
KR20140069133A (ko) 2014-06-09
EP3275443A1 (en) 2018-01-31
BR112014006702A2 (pt) 2017-06-13
US10166225B2 (en) 2019-01-01
NZ622722A (en) 2016-09-30
CA2848512A1 (en) 2013-03-28
TWI564009B (zh) 2017-01-01
AU2012312364B2 (en) 2017-11-09
IL231495A0 (en) 2014-04-30
ES2639093T3 (es) 2017-10-25
GEP201606523B (en) 2016-08-10
MX351133B (es) 2017-10-03
AU2012312364A1 (en) 2014-04-10
ZA201401728B (en) 2016-01-27
EA201490676A1 (ru) 2015-02-27
MX2014003027A (es) 2014-10-24
HK1201040A1 (en) 2015-08-21
UA115866C2 (uk) 2018-01-10
EP2758057B1 (en) 2017-05-31

Similar Documents

Publication Publication Date Title
AR087995A1 (es) Derivados de n-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}fenil)-n-(4-fluorofenil)ciclopropan-1,1-dicarboxamida
AR085195A1 (es) Metodo de tratamiento de cancer
AR100191A1 (es) Método para tratar adenocarcinoma de pulmón
CY1122610T1 (el) Αλκοξυ πυραζολια ως ενεργοποιητες διαλυτης γουανυλικης κυκλασης
CY1118340T1 (el) Αναστολεις κινασης
ECSP14013199A (es) Compuestos para el tratamiento y profilaxis de la enfermedad del virus sincicial respiratorio
CO6680699A2 (es) Derivados de amina para el control de plagas
EA201490647A1 (ru) Производные бензотиазол-6-илуксусной кислоты и их применение для лечения вич-инфекции
JOP20130256B1 (ar) مركبات سلفامويل اريل اميدات واستعمالها كمواد علاجية لمعالجة التهاب الكبد نوع بي
EA201391072A1 (ru) Производные фтор-пиридинона, полезные в качестве антибактериальных агентов
CY1118973T1 (el) Παραγωγα αμιδιου βενζοϊμιδαζολο-καρβοξυλικου οξεος για τη θεραπεια μεταβολικων ή καρδιαγγειακων νοσηματων
AR094277A1 (es) Derivados de fumarato sustituidos con deuterio
CO7141456A2 (es) Derivados de aril-sultamo como moduladores de rorc
EA201992884A2 (ru) Арильные, гетероарильные и гетероциклические соединения для лечения заболеваний
EA201300200A1 (ru) N-((6-аминопиридин-3-ил)метил)гетероарилкарбоксамиды в качестве ингибиторов калликреина в плазме
BR112014003237A2 (pt) compostos de indazol, composições e métodos de uso
AR093093A1 (es) Tratamientos y profilaxis para el sindrome de lisis tumoral
BR112015021027A2 (pt) compostos terapêuticos
EA201592200A1 (ru) Производные сульфамоилпирроламида и их применение в качестве медикаментов для лечения гепатита b
MX388641B (es) Inhibidores heterociclicos de erk1 y erk2 y su uso en el tratamiento del cancer.
AR077765A1 (es) Inhibidores de los virus flaviviridae
UA104677C2 (ru) Производные мочевины и их терапевтическое применение при лечении, среди прочего, заболеваний дыхательных путей
EA201490650A1 (ru) Фармацевтические композиции
AR084011A1 (es) Compuestos nitrogenados heterociclicos utiles para el tratamiento de infecciones por el virus sincitial respiratorio (rsv), proceso para prepararlos y composiciones farmaceuticas que los contienen
EA201790599A1 (ru) Соединения и композиции в качестве ингибиторов киназ

Legal Events

Date Code Title Description
FB Suspension of granting procedure